251 related articles for article (PubMed ID: 23576755)
1. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.
Karapetyan YE; Sferrazza GF; Zhou M; Ottenberg G; Spicer T; Chase P; Fallahi M; Hodder P; Weissmann C; Lasmézas CI
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):7044-9. PubMed ID: 23576755
[TBL] [Abstract][Full Text] [Related]
2. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-aminothiazoles as potent antiprion compounds.
Ghaemmaghami S; May BC; Renslo AR; Prusiner SB
J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192
[TBL] [Abstract][Full Text] [Related]
4. Identification of compounds inhibiting prion replication and toxicity by removing PrP
Biggi S; Pancher M; Stincardini C; Luotti S; Massignan T; Dalle Vedove A; Astolfi A; Gatto P; Lolli G; Barreca ML; Bonetto V; Adami V; Biasini E
J Neurochem; 2020 Jan; 152(1):136-150. PubMed ID: 31264722
[TBL] [Abstract][Full Text] [Related]
5. Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.
Hamanaka T; Nishizawa K; Sakasegawa Y; Oguma A; Teruya K; Kurahashi H; Hara H; Sakaguchi S; Doh-Ura K
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077650
[TBL] [Abstract][Full Text] [Related]
6. Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.
Ishibashi D; Ishikawa T; Mizuta S; Tange H; Nakagaki T; Hamada T; Nishida N
Neurotherapeutics; 2020 Oct; 17(4):1836-1849. PubMed ID: 32767031
[TBL] [Abstract][Full Text] [Related]
7. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
Hosokawa-Muto J; Kamatari YO; Nakamura HK; Kuwata K
Antimicrob Agents Chemother; 2009 Feb; 53(2):765-71. PubMed ID: 19015328
[TBL] [Abstract][Full Text] [Related]
8. Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions.
Chapuis J; Moudjou M; Reine F; Herzog L; Jaumain E; Chapuis C; Quadrio I; Boulliat J; Perret-Liaudet A; Dron M; Laude H; Rezaei H; Béringue V
Acta Neuropathol Commun; 2016 Feb; 4():10. PubMed ID: 26847207
[TBL] [Abstract][Full Text] [Related]
9. Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases.
Jackson WS; Borkowski AW; Watson NE; King OD; Faas H; Jasanoff A; Lindquist S
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14759-64. PubMed ID: 23959875
[TBL] [Abstract][Full Text] [Related]
10. Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.
Asante EA; Gowland I; Grimshaw A; Linehan JM; Smidak M; Houghton R; Osiguwa O; Tomlinson A; Joiner S; Brandner S; Wadsworth JDF; Collinge J
J Gen Virol; 2009 Mar; 90(Pt 3):546-558. PubMed ID: 19218199
[TBL] [Abstract][Full Text] [Related]
11. Developing Therapeutics for PrP Prion Diseases.
Giles K; Olson SH; Prusiner SB
Cold Spring Harb Perspect Med; 2017 Apr; 7(4):. PubMed ID: 28096242
[TBL] [Abstract][Full Text] [Related]
12. Prions from Sporadic Creutzfeldt-Jakob Disease Patients Propagate as Strain Mixtures.
Cassard H; Huor A; Espinosa JC; Douet JY; Lugan S; Aron N; Vilette D; Delisle MB; Marín-Moreno A; Peran P; Beringue V; Torres JM; Ironside JW; Andreoletti O
mBio; 2020 Jun; 11(3):. PubMed ID: 32546613
[TBL] [Abstract][Full Text] [Related]
13. Successes and challenges in phenotype-based lead discovery for prion diseases.
Ghaemmaghami S; Russo M; Renslo AR
J Med Chem; 2014 Aug; 57(16):6919-29. PubMed ID: 24762293
[TBL] [Abstract][Full Text] [Related]
14. Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies.
Candelise N; Schmitz M; Da Silva Correia SM; Arora AS; Villar-Piqué A; Zafar S; Llorens F; Cramm M; Zerr I
Expert Rev Mol Diagn; 2017 Oct; 17(10):897-904. PubMed ID: 28817974
[TBL] [Abstract][Full Text] [Related]
15. Approaches for discovering anti-prion compounds: lessons learned and challenges ahead.
Bolognesi ML; Legname G
Expert Opin Drug Discov; 2015 Apr; 10(4):389-97. PubMed ID: 25682812
[TBL] [Abstract][Full Text] [Related]
16. Styryl-based and tricyclic compounds as potential anti-prion agents.
Chung E; Prelli F; Dealler S; Lee WS; Chang YT; Wisniewski T
PLoS One; 2011; 6(9):e24844. PubMed ID: 21931860
[TBL] [Abstract][Full Text] [Related]
17. FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice.
Nakagaki T; Satoh K; Ishibashi D; Fuse T; Sano K; Kamatari YO; Kuwata K; Shigematsu K; Iwamaru Y; Takenouchi T; Kitani H; Nishida N; Atarashi R
Autophagy; 2013 Sep; 9(9):1386-94. PubMed ID: 23800841
[TBL] [Abstract][Full Text] [Related]
18. Combining autophagy stimulators and cellulose ethers for therapy against prion disease.
Abdulrahman BA; Tahir W; Doh-Ura K; Gilch S; Schatzl HM
Prion; 2019 Jan; 13(1):185-196. PubMed ID: 31578923
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a class of diketopiperazines as antiprion compounds.
Bolognesi ML; Ai Tran HN; Staderini M; Monaco A; López-Cobeñas A; Bongarzone S; Biarnés X; López-Alvarado P; Cabezas N; Caramelli M; Carloni P; Menéndez JC; Legname G
ChemMedChem; 2010 Aug; 5(8):1324-34. PubMed ID: 20540064
[TBL] [Abstract][Full Text] [Related]
20. Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity.
Ayrolles-Torro A; Imberdis T; Torrent J; Toupet K; Baskakov IV; Poncet-Montange G; Grégoire C; Roquet-Baneres F; Lehmann S; Rognan D; Pugnière M; Verdier JM; Perrier V
J Neurosci; 2011 Oct; 31(42):14882-92. PubMed ID: 22016521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
